Literature DB >> 31646125

Metformin: new insights into an archetypal cardiometabolic drug.

Andrew J Krentz1.   

Abstract

Entities:  

Year:  2017        PMID： 31646125      PMCID： PMC6768509          DOI： 10.1097/XCE.0000000000000129

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol        ISSN： 2162-688X


× No keyword cloud information.
  26 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Authors:  C Lamanna; M Monami; N Marchionni; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

3.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

4.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

7.  The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

Authors:  John B Buse; Ralph A DeFronzo; Julio Rosenstock; Terri Kim; Colleen Burns; Sharon Skare; Alain Baron; Mark Fineman
Journal:  Diabetes Care       Date:  2015-08-18       Impact factor: 19.112

Review 8.  Metformin: effects on micro and macrovascular complications in type 2 diabetes.

Authors:  Clifford J Bailey
Journal:  Cardiovasc Drugs Ther       Date:  2008-02-21       Impact factor: 3.727

Review 9.  Beneficial effects of metformin on haemostasis and vascular function in man.

Authors:  P J Grant
Journal:  Diabetes Metab       Date:  2003-09       Impact factor: 6.041

10.  Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.

Authors:  G Perriello; P Misericordia; E Volpi; A Santucci; C Santucci; E Ferrannini; M M Ventura; F Santeusanio; P Brunetti; G B Bolli
Journal:  Diabetes       Date:  1994-07       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.